Cogent Biosciences Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
COGT$31.64-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Series A Non-Voting Convertible PreferredStock · Series B Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 74,465 | $60,035 | — | $— | 86,124,249 | $86 | $801,059 | $246 | $(603,624) | $257,802 |
| Issuance of Series B non-voting convertible preferred stock and common stock, net of issuance costs of $11.6 million, in connection with the Private Placement | — | — | 12,280 | 87,364 | 17,717,997 | 18 | 126,034 | — | — | $213,416 |
| Exchange of common stock for Series B non-voting convertible preferred stock | — | — | 8,300 | 74,754 | (8,300,000) | (8) | (74,746) | — | — | — |
| Issuance of common stock under Employee Stock Purchase Plan | — | — | — | — | 71,150 | — | 356 | — | — | $356 |
| Unrealized gains on marketable securities | — | — | — | — | — | — | — | (285) | — | $(285) |
| Stock-based compensation expense | — | — | — | — | — | — | 9,393 | — | — | $9,393 |
| Net loss | — | — | — | — | — | — | — | — | (58,348) | $(58,348) |
| Balances at March 31, 2024 | 74,465 | $60,035 | 20,580 | $162,118 | 95,613,396 | $96 | $862,096 | $(39) | $(661,972) | $422,334 |
| Series A Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances at December 31, 2022 | 81,050 | $65,830 | 69,893,434 | $70 | $601,153 | $(104) | $(411,214) | $255,735 |
| Unrealized gains on marketable securities | — | — | — | — | — | 120 | — | 120 |
| Conversion of Series A non-voting preferred stock into common stock | (4,000) | (3,520) | 1,000,000 | 1 | 3,519 | — | — | — |
| Issuance of common stock under Employee Stock Purchase Plan | — | — | 39,228 | — | 313 | — | — | 313 |
| Issuance of common stock upon exercise of stock options | — | — | 14,128 | — | 132 | — | — | 132 |
| Stock-based compensation expense | — | — | — | — | 5,850 | — | — | 5,850 |
| Net loss | — | — | — | — | — | — | (38,587) | (38,587) |
| Balances at March 31, 2023 | 77,050 | $62,310 | 70,946,790 | $71 | $610,967 | $16 | $(449,801) | $223,563 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.